Angioedema Clinical Trials and Pipeline 2025: EMA, PDMA, FDA Approvals, Medication, NDA Approval, Therapies, ROA, MOA and Companies by DelveInsight

(Albany, United States) As per DelveInsight's assessment, globally, Angioedema pipeline constitutes 20+ key companies continuously working towards developing 20+ Angioedema treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

"Angioedema Pipeline Insight, 2025" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Angioedema Market.

The Angioedema Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Request for sample report @ https://www.delveinsight.com/sample-request/angioedema-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Some of the key takeaways from the Angioedema Pipeline Report:
• Angioedema Companies across the globe are diligently working toward developing novel Angioedema treatment therapies with a considerable amount of success over the years.
• Angioedema companies working in the treatment market are ADARx Pharmaceuticals, BioMarin Pharmaceutical, Intellia Therapeutics, Astria Therapeutics, Ionis Pharmaceuticals, KalVista Pharmaceuticals, CSL Behring, and others, are developing therapies for the Angioedema treatment
• Emerging Angioedema therapies in the different phases of clinical trials are- ADX-324, BMN 331, NTLA-2002, STAR-0215, Donidalorsen, Sebetralstat, CSL312, and others are expected to have a significant impact on the Angioedema market in the coming years.
• In January 2025, Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on advancing medicine with CRISPR-based therapies, has announced that the first patient has been dosed in the global Phase 3 study of NTLA-2002 for treating hereditary angioedema (HAE). NTLA-2002 is a proprietary investigational in vivo CRISPR-based therapy being developed as a single-dose treatment for this potentially life-threatening condition. Intellia plans to complete enrollment by the second half of 2025 and intends to submit a biologics license application (BLA) in 2026, with the goal of launching the therapy in the U.S. by 2027.
• In January 2025, KalVista Pharmaceuticals, Inc. (NASDAQ: KALV) announced that Japan's Ministry of Health, Labour and Welfare (MHLW) has granted sebetralstat Orphan Drug Designation. The company has also submitted a New Drug Application (NDA) for sebetralstat to the Agency. If approved, sebetralstat, a novel investigational oral plasma kallikrein inhibitor for the on-demand treatment of hereditary angioedema (HAE) attacks in adults and adolescents aged 12 years and older, will become the first oral on-demand treatment for HAE in Japan.
• In October 2024, Intellia Therapeutics, a US-based biotechnology company, launched the Phase III HAELO clinical trial for NTLA-2002, an investigational in-vivo gene editing therapy aimed at treating hereditary angioedema (HAE). This multinational, placebo-controlled study will evaluate the therapy's efficacy and safety in 60 adult participants diagnosed with Type I or Type II HAE.

Angioedema Overview
Angioedema is a condition characterized by sudden swelling beneath the skin or mucous membranes due to fluid accumulation. It commonly affects the face, lips, tongue, throat, and extremities but can also involve internal organs. The swelling is usually non-itchy but may be painful and, in severe cases, life-threatening if it leads to airway obstruction.

There are several types of angioedema: allergic (triggered by allergens like food, insect stings, or medications), hereditary (caused by genetic mutations affecting the complement system), drug-induced (such as from ACE inhibitors), and idiopathic (unknown cause). Symptoms may include swelling, difficulty breathing, abdominal pain, and, in some cases, anaphylaxis.

Diagnosis is based on clinical evaluation, medical history, and allergy or blood tests to identify underlying causes. Treatment depends on the type and severity of angioedema. Mild cases may resolve on their own or with antihistamines and corticosteroids, while severe cases require emergency care with epinephrine, oxygen support, and airway management. For hereditary angioedema, specialized treatments like C1-inhibitor therapy or bradykinin receptor antagonists are used.

Long-term management includes avoiding known triggers, medication adjustments, and preventive treatments for recurrent cases. Early recognition and appropriate intervention are crucial to preventing complications.

Get a Free Sample PDF Report to know more about Angioedema Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/angioedema-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Emerging Angioedema Drugs Under Different Phases of Clinical Development Include:
• ADX-324: ADARx Pharmaceuticals
• BMN 331: BioMarin Pharmaceutical
• NTLA-2002: Intellia Therapeutics
• STAR-0215: Astria Therapeutics
• Donidalorsen: Ionis Pharmaceuticals
• Sebetralstat: KalVista Pharmaceuticals
• CSL312: CSL Behring

Angioedema Route of Administration
Angioedema pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
• Inhalation
• Inhalation/Intravenous/Oral
• Intranasal
• Intravenous
• Intravenous/ Subcutaneous
• NA
• Oral
• Oral/intranasal/subcutaneous
• Parenteral
• Subcutaneous

Angioedema Molecule Type
Angioedema Products have been categorized under various Molecule types, such as
• Antibody
• Antisense oligonucleotides
• Immunotherapy
• Monoclonal antibody
• Peptides
• Protein
• Recombinant protein
• Small molecule
• Stem Cell
• Vaccine

Angioedema Pipeline Therapeutics Assessment
• Angioedema Assessment by Product Type
• Angioedema By Stage and Product Type
• Angioedema Assessment by Route of Administration
• Angioedema By Stage and Route of Administration
• Angioedema Assessment by Molecule Type
• Angioedema by Stage and Molecule Type

DelveInsight's Angioedema Report covers around 20+ products under different phases of clinical development like
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Further Angioedema product details are provided in the report. Download the Angioedema pipeline report to learn more about the emerging Angioedema therapies
https://www.delveinsight.com/sample-request/angioedema-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Some of the key companies in the Angioedema Therapeutics Market include:
Key companies developing therapies for Angioedema are - BioCryst Pharmaceuticals, KalVista Pharmaceuticals, Pharvaris, BioMarin Pharmaceutical, Ionis Pharmaceuticals Inc., Intellia Therapeutics, and others.

Angioedema Pipeline Analysis:
The Angioedema pipeline report provides insights into
• The report provides detailed insights about companies that are developing therapies for the treatment of Angioedema with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Angioedema Treatment.
• Angioedema key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Angioedema Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Angioedema market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Angioedema drugs and therapies
https://www.delveinsight.com/sample-request/angioedema-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Angioedema Pipeline Market Drivers
• Increasing Prevalence of Angioedema, increase in research and developmental activities are some of the important factors that are fueling the Angioedema Market.

Angioedema Pipeline Market Barriers
• However, high-cost associated with the treatment, misdiagnosis of the disease and other factors are creating obstacles in the Angioedema Market growth.

Scope of Angioedema Pipeline Drug Insight
• Coverage: Global
• Key Angioedema Companies: ADARx Pharmaceuticals, BioMarin Pharmaceutical, Intellia Therapeutics, Astria Therapeutics, Ionis Pharmaceuticals, KalVista Pharmaceuticals, CSL Behring, and others
• Key Angioedema Therapies: ADX-324, BMN 331, NTLA-2002, STAR-0215, Donidalorsen, Sebetralstat, CSL312, and others
• Angioedema Therapeutic Assessment: Angioedema current marketed and Angioedema emerging therapies
• Angioedema Market Dynamics: Angioedema market drivers and Angioedema market barriers

Request for Sample PDF Report for Angioedema Pipeline Assessment and clinical trials
https://www.delveinsight.com/sample-request/angioedema-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Table of Contents
1. Angioedema Report Introduction
2. Angioedema Executive Summary
3. Angioedema Overview
4. Angioedema- Analytical Perspective In-depth Commercial Assessment
5. Angioedema Pipeline Therapeutics
6. Angioedema Late Stage Products (Phase II/III)
7. Angioedema Mid Stage Products (Phase II)
8. Angioedema Early Stage Products (Phase I)
9. Angioedema Preclinical Stage Products
10. Angioedema Therapeutics Assessment
11. Angioedema Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Angioedema Key Companies
14. Angioedema Key Products
15. Angioedema Unmet Needs
16 . Angioedema Market Drivers and Barriers
17. Angioedema Future Perspectives and Conclusion
18. Angioedema Analyst Views
19. Appendix
20. About DelveInsight

Trending Reports:
• Phosphoglucomutase Pgm 1 Deficiency Market: https://www.delveinsight.com/report-store/phosphoglucomutase-pgm-1-deficiency-market
• Polypoidal Choroidal Vasculopathy Market: https://www.delveinsight.com/report-store/polypoidal-choroidal-vasculopathy-market
• Tay-sachs Disease Or Gm2 Gangliosidosis Market: https://www.delveinsight.com/report-store/tay-sachs-disease-pipeline-insight
• Fibromyalgia Market: https://www.delveinsight.com/report-store/fibromyalgia-market
• Dermal Erythema Market: https://www.delveinsight.com/report-store/cutaneous-lupus-erythematosus-market
• Automated External Defibrillators Market: https://www.delveinsight.com/report-store/external-defibrillators-market
• Androgenetic Alopecia Market: https://www.delveinsight.com/report-store/androgenetic-alopecia-market
• Hyperhidrosis Market: https://www.delveinsight.com/report-store/axillary-hyperhidrosis-ahh-market
• Palmar Hyperhidrosis Market: https://www.delveinsight.com/report-store/palmar-hyperhidrosis-market
• Chronic Lymphocytic Leukemia Cll Market: https://www.delveinsight.com/report-store/chronic-lymphocytic-leukemia-cll-market
• Neuromodulation Devices Market: https://www.delveinsight.com/report-store/neuromodulation-devices-market
• Catheter-related Bloodstream Infections Market: https://www.delveinsight.com/report-store/catheter-related-bloodstream-infection-market
• Chronic Myelogenous Leukemia Market: https://www.delveinsight.com/report-store/chronic-myeloid-leukemia-market
• Fuchs Dystrophy Market: https://www.delveinsight.com/report-store/fuchs-endothelial-corneal-dystrophy-fecd-market
• Graft Versus Host Disease Market: https://www.delveinsight.com/report-store/graft-versus-host-disease-gvhd-market
• Minimal Residual Disease Market: https://www.delveinsight.com/report-store/minimal-residual-disease-market
• Neurostimulation Devices Market: https://www.delveinsight.com/report-store/neurostimulation-devices-market
• Pressure Ulcers Market: https://www.delveinsight.com/report-store/pressure-ulcers-market
• Progressive Multifocal Leukoencephalopathy Market: https://www.delveinsight.com/report-store/progressive-multifocal-leukoencephalopathy-market
• Acoustic Neuroma Market: https://www.delveinsight.com/report-store/acoustic-neuroma-market
• Apheresis Market: https://www.delveinsight.com/report-store/apheresis-market
• Bone Anchored Hearing Systems Market: https://www.delveinsight.com/report-store/bone-anchored-hearing-systems-market

Contact Us:
Ankit Nigam
Manager Marketing
info@delveinsight.com
+14699457679
https://www.delveinsight.com/report-store.php
AACR Conference Coverage: https://www.delveinsight.com/aacr-annual-meeting

About DelveInsight
DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.

This release was published on openPR.